News & Announcements
-
Imaging Biometrics and MCW Awarded NIH Grant
Principal Investigator, Kathleen Schmainda, PhD, MCW professor of Biophysics, will leverage her foundational work in perfusion MRI technologies to more precisely identify brain tumor burden and provide earlier treatment response assessment over what is currently available. The grant’s objectives also include incorporating artificial intelligence capabilities for streamlined and automated processing.
-
IB’s Delta T1: A Quantitative and Automated Solution to Assess Brain Tumor Burden
Delta T1 on par with central reader analysis but offers substantial time and cost savings.
-
Total Voting Rights
/**/ RNS Number : 0358D IQ-AI Limited 28 February 2022 28 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Total Voting Rights In accordance with the Financial Conduct Authority’s Disclosure and Transparency Rules, IQ-AI announces that the Company has 182,621,390 ordinary shares of 1p each in issue, none of which are held…
-
Issue of shares to Mayo Clinic
/**/ RNS Number : 9343A IQ-AI Limited 08 February 2022 8 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Issue of shares to Mayo Clinic Further to the Company’s announcement dated 9 November 2020, IQ-AI announces the allotment of 113,781 ordinary shares of 1p each in IQ-AI (the “New Ordinary Shares”) to…
-
Director/PDMR Shareholding
/**/ RNS Number : 3367X IQ-AI Limited 04 January 2022 4 January 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Director/PDMR Shareholding IQ-AI announces that Michael Schmainda, Director of IQAI and CEO of Imaging Biometrics, has been granted an option to subscribe for 5,969,792 ordinary shares of 1p each in the Company (“Ordinary…